<p>Join Head of US Capital Markets Research, Mark Odendahl and biotech analysts Brian Abrahams and Gregory Renza, as they explore the dynamic biotech sector landscape in H2 2023. </p><p>This episode was originally broadcast on Industries in Motion, the RBC podcast. </p>

Join Head of US Capital Markets Research, Mark Odendahl and biotech analysts Brian Abrahams and Gregory Renza, as they explore the dynamic biotech sector landscape in H2 2023. This episode was originally broadcast on Industries in Motion, the RBC podcast.

Biotech Halftime Report: A Winding Road Ahead

Perspectives from the cutting edge of biotech and pharma.

The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series.

Lead today. Define tomorrow.

Business

News

Investing

Business News

Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.

Share Biotech Halftime Report: A Winding Road Ahead

Sign up to save your podcasts

Biotech Halftime Report: A Winding Road Ahead

Biotech Halftime Report: A Winding Road Ahead

More shows like Pathfinders in Biopharma

Motley Fool Money

WSJ Your Money Briefing

Exchanges

Odd Lots

WSJ Tech News Briefing

a16z Podcast

The Long Run with Luke Timmerman

The Readout Loud

Wall Street Breakfast

Thoughts on the Market

The Journal.

BioCentury This Week

RBC's Markets in Motion

Biotech Hangout

Industries in Motion

Powering Sustainable Ideas

The Markets

Strategic Alternatives

The Top Line

Macro Minutes